Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.
Noboru YamamotoShigehisa KitanoTakafumi KoyamaMasafumi IkedaHidenori MizugakiTakatsugu NarikiyoYuki YamaguchiTakaaki IshidaRyoko TakuboChika OgamiMayuko SekiyaYuki NakagawaYasutoshi KubokiPublished in: Journal for immunotherapy of cancer (2024)
With no DLTs, AMY109 plus atezolizumab was well tolerated in patients with advanced solid tumors, with no new safety signals. AMY109 showed a dose-proportional increase in exposure. The PRs in two patients were durable.